Cell therapy for Refractory Lymphoid Malignancies

Phase 1

Recruiting

• Conditions: Condition 1: Hodgkin lymphoma. Condition 2: Follicular lymphoma. Condition 3: Non-follicular lymphoma.; Hodgkin lymphoma; Follicular lymphoma; Non-follicular lymphoma

• Registration Number: IRCT20140818018842N26
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Age 18 years or older
adequate organ function at the time of infusion
After the failure of at least 2 prior lines of therapy
Histologically confirmed malignant lymphoma
Adequate performance score: KPS >70 or ECOG 0-2

Exclusion Criteria

CNS lymphoma
HIV patients
Patients with a history of autoimmune disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of Patients With Grades 3-5 of Natural Killer cell infusion-related Adverse Events. Timepoint: Daily during the first seven days after the injection and then weekly until 28 days after the injection. Method of measurement: History, Physical exam, and lab test.;Number of Patients With Grades III-IV Acute Graft versus Host Disease. Timepoint: Daily during the first seven days after the injection and then weekly until 3 months after intervention. Method of measurement: History, Physical exam, and lab test.